Compare Abeona Therapeutics Inc (ABEO) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Marsh & McLennan Companies, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Marsh & McLennan Companies, Inc. trades at $178.7 (market cap $85.76B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 229.7× Abeona Therapeutics Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.02% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MRSH | |
|---|---|---|
Market Cap | $373.32M | $85.76B |
Sector | Health | Financials |
52-Week High | $7.23 | $214.71 |
52-Week Low | $4.17 | $157.32 |
Enterprise Value | $228.22M | $106.60B |
Dividend Yield | — | 2.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Marsh (MRSH) trades at $178.00, showing modest daily weakness (-0.3%) but maintaining a bullish technical trend above key support levels. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $3.29 exceeding expectations, and robust profitability metrics with 14.26% net income margin and 27.42% ROE. Recent acquisition of TriBridge Partners strengthens advisory capabilities while dividend payments provide shareholder returns.
Marsh presents a compelling investment case with analyst consensus target of $192.00 offering 7.9% upside potential. The stock trades at reasonable valuation multiples (P/E 21.84, P/S 3.12) for its quality profile, though rising costs and premium valuation warrant monitoring. Institutional sentiment remains positive with 11 buy ratings outweighing 1 sell recommendation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
